International validation of the EORTC QLQ-CLL17 questionnaire for assessment of health-related quality of life for patients with chronic lymphocytic leukaemia.

Autor: Oerlemans S; Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands., Efficace F; Health Outcomes Research Unit, Italian Group for Adult Hematologic Diseases (GIMEMA) Data Centre, Rome, Italy., Kieffer JM; Department of Psychosocial Research & Epidemiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Kyriakou C; University College London Hospital, London, UK., Xochelli A; Institute of Applied Biosciences, Center for Research and Technology Hellas, Thessaloniki, Greece., Levedahl K; Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden., Petranovic D; Clinical Hospital Center Rijeka, University of Rijeka, Rijeka, Croatia., Borges FC; Department of Epidemiology and National Cancer Registry (RON), Instituto Português de Oncologia de Lisboa Francisco Gentil, E.P.E, Lisbon, Portugal., Bredart A; Institut Curie - Psycho-Oncology Unit, Paris University, Paris, France.; Psychopathology and Health Process Laboratory (LPPS) (UR 4057), PSL University, Paris, France., Shamieh O; Department of Palliative Medicine, King Hussein Cancer Center, Amman, Jordan., Gziskevicius L; University Hospital, Vilnius, Lithuania., Lehmann J; University Hospital of Psychiatry II, Medical University of Innsbruck, Innsbruck, Austria., Scholz CW; Hematology and Oncology, Vivantes Klinikum Am Urban, Berlin, Germany., Caocci G; Hematology, Businco Hospital, University of Cagliari, Cagliari, Italy., Molica S; Azienda Ospedalier Ciaccio, Catanzaro, Italy., Stamatopoulos K; Institute of Applied Biosciences, Center for Research and Technology Hellas, Thessaloniki, Greece., Panteliadou AK; Hematology Department and HCT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece., Papaioannou M; Hematology Unit, 1st Dept of Internal Medicine, AUTH, AHEPA Hospital, Thessaloniki, Greece., Alrjoob W; Department of Palliative Medicine, King Hussein Cancer Center, Amman, Jordan., Baliakas P; Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden., Rosenquist R; Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.; Clinical Genetics, Karolinska University Hospital, Stockholm, Sweden., Malak S; Hôpital René Huguenin-Institut Curie - Hématologie, Saint-Cloud, France., Miranda A; Department of Epidemiology and National Cancer Registry (RON), Instituto Português de Oncologia de Lisboa Francisco Gentil, E.P.E, Lisbon, Portugal., Cocks K; York Trials Unit, University of York, York & Adelphi Values, Cheshire, UK., van de Poll-Franse L; Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands.; Department of Psychosocial Research & Epidemiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of Medical and Clinical Psychology, Tilburg University, Tilburg, The Netherlands.
Jazyk: angličtina
Zdroj: British journal of haematology [Br J Haematol] 2022 May; Vol. 197 (4), pp. 431-441. Date of Electronic Publication: 2022 Mar 07.
DOI: 10.1111/bjh.18072
Abstrakt: Selecting the most appropriate chronic lymphocytic leukaemia (CLL) treatment is challenging. Patient-reported health-related quality of life (HRQoL) is therefore a critical aspect to consider. This international study by the European Organization for Research and Treatment of Cancer (EORTC) tested the psychometric properties of a newly developed measure for CLL patients: the EORTC QLQ-CLL17 to supplement the core questionnaire (EORTC QLQ-C30). Patients with CLL (n = 341) from 12 countries completed the QLQ-C30, QLQ-CLL17 and a debriefing questionnaire. Sociodemographic and clinical data were recorded from medical records. A high percentage (30%-66%) reported symptoms and/or worries (e.g. aches/pains in muscles, lack of energy and worry/fears about health). Confirmatory factor analysis showed an acceptable to good fit of the 17 items on the three scales (i.e. symptom burden, physical condition/fatigue and worries/fears about health and functioning). Completion took on average 8 min. Test-retest and convergent validity was demonstrated. The QLQ-CLL17 differentiated between patients with an Eastern Cooperative Oncology group (ECOG) performance of 0 versus 1-3 (p's < 0.01 and clinically relevant). The newly developed EORTC QLQ-CLL17 will increase sensitivity of HRQoL assessment in patients with CLL. Implementation of this questionnaire both in clinical research and practice will help to generate unique clinically relevant data to better inform CLL treatment decision-making.
(© 2022 British Society for Haematology and John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz: